Compare Archer-Daniels-Midland Co (ADM) vs BioNano Genomics Inc (BNGO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Archer-Daniels-Midland Co vs BioNano Genomics Inc — how do they compare? Archer-Daniels-Midland Co trades at $80.39 (market cap $38.78B), while BioNano Genomics Inc trades at $1.2 (market cap $13.66M). The key difference: Archer-Daniels-Midland Co is far larger — about 2838.9× BioNano Genomics Inc's market cap, and Archer-Daniels-Midland Co pays a 2.59% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| ADM | BNGO | |
|---|---|---|
Market Cap | $38.78B | $13.66M |
Sector | Consumer Staples | Health |
52-Week High | $87.32 | $4.92 |
52-Week Low | $56.00 | $1.06 |
Enterprise Value | $47.03B | $16.26M |
Dividend Yield | 2.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADM trades at $79.41, down 1.34% today, with a bullish technical signal and strong earnings beats in recent quarters. The company reported Q2 2026 EPS of $1.84, exceeding expectations, and raised its full-year outlook, driven by biofuels and crushing margins. Valuation ratios like P/E of 21.98 and P/S of 0.48 suggest reasonable pricing relative to peers. Cash flow improved in 2025 with net cash flow of $1.58 billion.
The outlook is positive with analyst consensus price target of $88.00, implying upside. Key opportunities include growth in AgTech and biofuels, while risks involve execution challenges and volatile commodity markets. The stock offers a dividend yield supported by consistent payments, but investors should monitor margin pressures from input costs.
BNGO trades at $1.19, up 2.59% today, with bullish technical signals from moving averages. The company shows improving financials with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable. Recent earnings have consistently beaten expectations, and analyst sentiment is positive with 57% buy ratings. Key developments include debt retirement and scientific publications highlighting optical genome mapping adoption.
The outlook is cautiously optimistic given improving fundamentals and positive analyst coverage, but significant risks remain due to persistent losses and negative cash flow. Investment opportunity lies in the company's technology adoption growth, while primary risks include profitability challenges and competitive pressures in the genomics space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Archer-Daniels-Midland Co
Archer-Daniels Midland is a major processor of oilseeds, corn, wheat, and other agricultural commodities. Additionally, the company owns an extensive network of logistical assets to store and transport crops around the globe. ADM also runs a nutrition business that focuses on both human and animal ingredients. The company is also a large producer of corn-based sweeteners, starches, and ethanol.
Read more on ADM →About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →
